Payment overview · 2025
General Payments
$736.25
28 reported records · 12 companies
Healthcare provider profile · identity verified
Tamara Rae Brunk, APRN-CNS
Physician Assistants & Advanced Practice Nursing Providers|Clinical Nurse Specialist|Critical Care Medicine · ARDMORE, OK · NPI 1336477728
Verified facts
What the public records show
CMS Open Payments records show Tamara Rae Brunk, APRN-CNS received $736.25 in general payments during 2025 across 28 reported records.
Endologix LLC accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Endologix LLC | Unresolved — no canonical attribution shown | $173.06 | 23.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $108.34 | 14.7% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $93.15 | 12.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $79.13 | 10.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.29 | 8.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.43 | 5.8% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $41.50 | 5.6% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.53 | 5.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.79 | 3.8% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $25.92 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.75 | 2.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.36 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $736.25 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $173.06 | 2 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $173.06 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $108.34 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $93.15 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $79.13 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.43 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.43 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $41.50 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.72 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 40 |
| Gabapentin | Gabapentin | 110 | 27 |
| Alprazolam | Alprazolam | 106 | 23 |
| Omeprazole | Omeprazole | 100 | 40 |
| Montelukast Sodium | Montelukast Sodium | 89 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 30 |
| Furosemide | Furosemide | 81 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 80 | 33 |
| Potassium Chloride | Potassium Chloride | 79 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 75 | 22 |
| Buspirone Hcl | Buspirone Hcl | 73 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 24 |
| Ozempic | Semaglutide | 67 | 14 |
| Mounjaro | Tirzepatide | 65 | suppressed |
| Metformin Hcl | Metformin Hcl | 62 | 20 |
| Losartan Potassium | Losartan Potassium | 61 | 22 |
| Meloxicam | Meloxicam | 59 | 23 |
| Prednisone | Prednisone | 57 | 44 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 22 |
| Lisinopril | Lisinopril | 55 | 21 |
| Pregabalin | Pregabalin | 54 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 19 |
| Carvedilol | Carvedilol | 50 | 15 |
| Sucralfate | Sucralfate | 49 | 17 |
| Azithromycin | Azithromycin | 45 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 15 |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Glipizide | Glipizide | 35 | 11 |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Simvastatin | Simvastatin | 33 | 12 |
| Tramadol Hcl | Tramadol Hcl | 33 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Eliquis | Apixaban | 32 | 11 |
| Ibuprofen | Ibuprofen | 32 | 16 |
| Estradiol | Estradiol | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 12 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Famotidine | Famotidine | 26 | 13 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 14 |
| Ezetimibe | Ezetimibe | 22 | 11 |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Taltz Autoinjector | Ixekizumab | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $736.25 · 28 records | Endologix LLC | DUPIXENT, ENDOCROSS Device, Flexitouch Plus, Hillrom - Monarch Airway Clearance System, INSPIRE, Kerendia, Korlym, NUZYRA, Nimbl, OTEZLA, Ozempic, REPATHA, Torus Stent Graft System, VERQUVO, WATCHMAN Access System, Wegovy, XHANCE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error